Patient characteristics | Intervention group | Control group | Total |
---|---|---|---|
(n = 365) | (n = 371) | (n = 736) | |
Age (years), mean (SD) | 74.4 (9.5) | 72.8 (9.3) | 73.5 (9.4) |
Sex, n (%) | |||
 Male | 205 (56.2) | 200 (53.9) | 405 (55.0) |
 Female | 160 (43.8) | 171 (46.1) | 331 (45.0) |
CHA2DS2-VASc scorea | |||
  = 1, n (%) | 9 (3.0) | 12 (4.1) | 21 (3.5) |
  > 1, n (%) | 292 (97.0) | 282 (95.9) | 574 (96.5) |
Long-term indication for oral anticoagulation, n (%) | |||
 Atrial fibrillation | 302 (82.7) | 295 (79.5) | 597 (81.1) |
 Recurrent venous thrombosis | 32 (8.8) | 40 (10.8) | 72 (9.8) |
 Recurrent pulmonary embolism | 31 (8.5) | 30 (8.1) | 61 (8.3) |
 Mechanical heart prosthesis | 29 (7.9) | 28 (7.5) | 57 (7.7) |
 Intracardiac thrombus | 3 (0.8) | 4 (1.1) | 7 (1.0) |
 Other indications | 33 (9.0) | 34 (9.2) | 67 (9.1) |
Antithrombotic medication, n (%) | |||
 Coumarin derivates | 346 (94.8) | 348 (93.8) | 694 (94.3) |
 Dabigatran | 10 (2.7) | 3 (0.8) | 13 (1.8) |
 Rivaroxaban | 7 (1.9) | 16 (4.3) | 23 (3.1) |
 Other | 2 (0.5) | 4 (1.1) | 6 (0.8) |
Last INR measured within therapeutic target range, n (%) | 240 (65.8) | 239 (64.4) | 479 (65.1) |
INR self-management, n (%) | 39 (10.7) | 46 (12.4) | 85 (11.5) |
Migration backgroundb, n (%) | 27 (7.4) | 24 (6.5) | 51 (6.9) |
Patient compliancec, n (%) | |||
 Very good compliance | 308 (84.4) | 266 (71.7) | 574 (80.0) |
 Good compliance | 51 (14.0) | 86 (23.2) | 137 (18.6) |
 Non-compliant | 6 (1.6) | 17 (4.6) | 23 (3.1) |
 No assessment available | 0 | 2 (0.5) | 2 (0.3) |